Evidence map›Paper›PMID 40976999›Full record

ReviewEndocrinology, diabetes & metabolism2025

Unveiling Molecular Mechanisms Underlying Obesity-Associated Systemic Lupus Erythematosus.

Roshvin Kailashnath Pillai, Rishvini Kailashnath Pillai, Vinibha Rajakumari Illankovan, Vinod Balasubramaniam, A M Alabsi, Anupam Biswas, Hari Kumar Darnal, Saminathan Kayarohanam, Madhan Kumar Soutallu Janakiram, Vetriselvan Subramaniyan

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Endocrinology, diabetes & metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Roshvin Kailashnath PillaiFaculty of Medicine, MAHSA University, Jenjarom, Selangor, Malaysia.
Rishvini Kailashnath PillaiFaculty of Medicine, MAHSA University, Jenjarom, Selangor, Malaysia.
Vinibha Rajakumari IllankovanCentre for Pre-University Studies, MAHSA University, Jenjarom, Selangor, Malaysia.
Vinod BalasubramaniamJeffrey Cheah School of Medicine and Health Sciences, Monash University Malaysia, Jalan Lagoon Selatan, Bandar Sunway, Subang Jaya, Selangor, Malaysia.
A M AlabsiManagement and Science University, University Drive, Off Persiaran Olahraga, Shah Alam, Selangor, Malaysia.
Anupam BiswasFaculty of Medicine, Department of Physiology, AIMST University, Bedong, Kedah, Malaysia.
Hari Kumar DarnalInternational Medical School, Management and Science University, Shah Alam, Selangor, Malaysia.
Saminathan KayarohanamFaculty of Bioeconomics, Food & Health Science, University Geomatika Malaysia, Prima Peninsula, Kuala Lumpur, Malaysia.
Madhan Kumar Soutallu JanakiramDepartment of Anatomy, Faculty of Medicine, Manipal University College, Bukit Baru, Malaysia.
Vetriselvan SubramaniyanDepartment of Biomedical Sciences Sir Jeffrey Cheah Sunway Medical School Faculty of Medical and Life Sciences, Sunway University, Subang Jaya, Selangor, Malaysia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSystemic lupus erythematosus (SLE) is a chronic autoimmune disease primarily affecting women of childbearing age, characterised by relapsing inflammation across multiple organ systems. Its aetiology involves genetic and environmental factors that trigger immune dysregulation, leading to the excessive release of autoantibodies.

objectiveThis study discusses the pathogenesis, diagnosis, management and emerging therapeutic targets in SLE, with a focus on metabolic reprogramming and the role of obesity.

methodsDiagnosis is based on clinical and laboratory findings, with the EULAR and ACR criteria being the most advanced. SLE management requires individualised treatment, addressing the severity and organs affected.

resultsSLE presents with symptoms ranging from mild skin rashes to severe conditions like pulmonary hypertension and kidney failure. Advances in care have improved outcomes, with 80%-90% of patients achieving normal life expectancy with proper treatment. Metabolic reprogramming in immune cells is crucial to SLE pathogenesis, as altered glycolysis and fatty acid oxidation contribute to inflammation. DISCUSSION: Obesity is recognised to aggravate SLE by fostering chronic inflammation, immunological dysregulation and dysbiosis of the gut microbiota. These situations may exacerbate autoimmunity, especially in genetically predisposed individuals. It is suggested that obesity significantly contributes to the pathogenesis of SLE, and additional study should investigate metabolic therapy aimed at obesity and microbiota to re-establish immunological equilibrium and mitigate disease development.

conclusionTargeting metabolic pathways may offer new therapeutic options for improved disease management. Particular abnormalities in gut microbiota, characterised by reduced diversity and an increase in pro-inflammatory species, influence obesity-related immunological dysregulation in systemic lupus erythematosus and may present new therapeutic targets.

Indexed as

Lupus Erythematosus, SystemicObesityFemaleGastrointestinal MicrobiomeHumansInflammationautoimmune diseaseimmune dysregulationmetabolic reprogrammingobesity‐induced inflammationsystemic lupus erythematosus (SLE)

Identifiers

PMID40976999
PMCPMC12451022

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.